The Set up and the Triggers: An Update on the Risk Factors for Giant Cell Arteritis DOI

Mary Labowsky,

Ben Harnke

Current Neurology and Neuroscience Reports, Journal Year: 2024, Volume and Issue: 25(1)

Published: Dec. 14, 2024

Language: Английский

Risk of new-onset polymyalgia rheumatica following COVID-19 vaccination in South Korea: a self-controlled case-series study DOI Creative Commons
Jieun Woo, Meehyun Kim,

HyunJoo Lim

et al.

RMD Open, Journal Year: 2025, Volume and Issue: 11(2), P. e005138 - e005138

Published: April 1, 2025

Background While several studies have reported some cases of polymyalgia rheumatica (PMR) following COVID-19 vaccination, using large databases are lacking. Objectives To investigate the risk PMR after vaccination self-controlled case series (SCCS) analysis Methods We used National Health Insurance Database, linked with registry between February 2021 and August 2023, to identify adults aged 50 years or older who received at least one dose vaccine subsequently diagnosed within observation period, defined as 240 days first vaccine. The window was 28 each control encompassed remainder period. Incidence rate ratios (IRRs) were estimated conditional Poisson regression 95% CIs, stratified by type. Results Among 44 818 078 recipients, 376 patients PMR. indicated that not associated an increased (IRR, 0.74; CI 0.59 0.94). Rather, slightly reduced (0.52; 0.34 0.79), no significant association other doses (0.83; 1.16 for second dose, 0.77, 0.48 1.25 third dose). Conclusion In this nationwide SCCS, there vaccination. these findings support safety vaccines, interpretation decreased should be cautious.

Language: Английский

Citations

0
Polymyalgia rheumatica following COVID-19 vaccination: Case series of 3 patients and literature review on polymyalgia rheumatica induced by various vaccines DOI Creative Commons
Laure Irani,

Mira Bou Karroum,

Yara Chehab

et al.

Medicine, Journal Year: 2024, Volume and Issue: 103(43), P. e40204 - e40204

Published: Oct. 25, 2024

Since the onset of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic in 2019, considerable resources have been devoted to developing vaccines reduce related deaths and burden disease. Various vaccine formulations eventually became available were approved for clinical use. In this article, we conducted a review polymyalgia rheumatica (PMR) cases induced by different COVID-19 [Pfizer: BNT162b2, AstraZeneca: ChAdOx1-S, Moderna: mRNA-1273, Janssen: Ad26.COV2.S)], as well non-COVID-19 vaccines, such influenza, zoster, hepatitis B, tetanus vaccines. Additionally, article investigates 3 with presentations suggestive PMR following mRNA vaccination. This study aims offer valuable insights through sharing diagnostic therapeutic experiences.

Language: Английский

Citations

1
COVID-19 in patients with interstitial lung disease DOI
Eirini Vasarmidi, Pierre Le Guen,

Tiphaine Goletto

et al.

European Respiratory Society eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 27, 2024

Language: Английский

Citations

0
A bibliometric analysis from 2004 to 2024 reveals research hotspots and trends in the immunotherapy for vasculitis DOI Creative Commons
Ruijuan Li, Ran Zhang,

Yuheng Jia

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: Sept. 25, 2024

Using bibliometric analysis, this study attempted to provide an overview of the current state research and key findings regarding immunotherapy for vasculitis in general. We gathered literature from Web Science (WOS) database covering last 20 years (2004-2024) pertaining vasculitis, we used Citespace evaluate mapping knowledge. The demonstrated that there were 572 articles concerning with a faster growth after 2018. USA, Assistance Publique Hopitaux Paris, Cornelia M are nation, organization, writer highest number publications. Daxini A (2018) is most frequently mentioned reference as well (26). Prominent universities developed nations form finest alliances on researches. Immune checkpoint inhibitors, Wegener's granulomatosis, systemic lupus erythematosus Three hotspots field.

Language: Английский

Citations

0
Infective agents and polymyalgia rheumatica: key discussion points emerging from a narrative review of published literature DOI Creative Commons
Ciro Manzo, Marco Isetta, Alberto Castagna

et al.

Reumatologia/Rheumatology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 6, 2024

The aetiology of polymyalgia rheumatica (PMR) is unknown. Recently, reports on cases PMR following the coronavirus disease 2019 (COVID-19) have revived role infection as an aetiological or triggering factor. It estimated that patients with manifestations giant cell arteritis (GCA) in < 20% cases. To date, little known potential infectious agents facilitating this association. Given background, we performed a review published literature. Our first aim was to and discuss relationship between infective agents. Secondly, compared data PMR-only overlapping GCA seek any commonalities differences regarding type agent these two subgroups.

Language: Английский

Citations

0
The Set up and the Triggers: An Update on the Risk Factors for Giant Cell Arteritis DOI

Mary Labowsky,

Ben Harnke

Current Neurology and Neuroscience Reports, Journal Year: 2024, Volume and Issue: 25(1)

Published: Dec. 14, 2024

Language: Английский

Citations

0